Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice

Li,Wen-Cong; Zhao,Su-Xian; Ren,Wei-Guang; Zhang,Yu-Guo; Wang,Rong-Qi; Kong,Ling-Bo; Zhang,Qing-Shan; Nan,Yue-Min

doi:10.3892/etm.2021.10262

Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice

Authors:
- Wen-Cong Li
- Su-Xian Zhao
- Wei-Guang Ren
- Yu-Guo Zhang
- Rong-Qi Wang
- Ling-Bo Kong
- Qing-Shan Zhang
- Yue-Min Nan
View Affiliations

Affiliations: The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: June 3, 2021 https://doi.org/10.3892/etm.2021.10262
Article Number: 830
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic steatohepatitis (NASH) has no approved therapy. The farnesoid X nuclear receptor (FXR) agonist obeticholic acid (OCA) has shown promise as a drug for NASH, but can adversely affect plasma lipid profiles. Therefore, the present study aimed to investigate the effects and underlying mechanisms of OCA in combination with simvastatin (SIM) in a high‑fat diet (HFD)‑induced model of NASH. C57BL/6J mice were fed with a HFD for 16 weeks to establish the NASH model. The mice were randomly divided into the following five groups: HFD, HFD + OCA, HFD + SIM, HFD + OCA + SIM and control. After 16 weeks, the mice were sacrificed under anesthesia. The ratios of liver weight to body weight (Lw/Bw) and of abdominal adipose tissue weight to body weight were calculated. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides and low‑density lipoprotein were measured. Liver sections were stained with hematoxylin and eosin. The protein levels of FXR, small heterodimeric partner (SHP) and cytochrome P450 family 7 subfamily A member 1 (CYP7A1) in the liver were detected by western blotting, while the mRNA levels of FXR, SHP, CYP7A1, bile salt export pump, interleukin‑6 (IL‑6), tumor necrosis factor‑α (TNF‑α), sterol regulatory element binding protein‑1 (SREBP1) and fatty acid synthase (FASN) were examined by reverse transcription‑quantitative polymerase chain reaction. The administration of OCA with or without SIM reduced the liver inflammation score compared with those of the HFD and HFD + SIM groups, with no significant difference between the HFD + OCA and HFD + OCA + SIM groups. The steatosis score followed similar trends to the inflammation score. In HFD‑fed mice, OCA combined with SIM prevented body weight gain compared with that in HFD and HFD + OCA groups, and reduced the Lw/Bw ratio compared with that in the HFD and HFD + SIM groups. In addition to preventing HFD‑induced increases of ALT and AST, the combination of OCA and SIM reduced the mRNA levels of IL‑6, TNF‑α, SREBP1 and FASN. On the basis of these results, it may be concluded that the strategy of combining OCA with SIM represents an effective pharmacotherapy for NASH.

View Figures

View References

1	Rinella ME: Nonalcoholic fatty liver disease: A systematic review. JAMA. 313:2263–2273. 2015.PubMed/NCBI View Article : Google Scholar
2	Diehl AM and Day C: Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 377:2063–2072. 2017.PubMed/NCBI View Article : Google Scholar
3	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update. Zhonghua Gan Zang Bing Za Zhi. 26:195–203. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
4	Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK and Dierkhising RA: Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 141:1249–1253. 2011.PubMed/NCBI View Article : Google Scholar
5	Lonardo A, Nascimbeni F, Mantovani A and Targher G: Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 68:335–352. 2018.PubMed/NCBI View Article : Google Scholar
6	Ratziu V, Goodman Z and Sanyal A: Current efforts and trends in the treatment of NASH. J Hepatol. 62 (Suppl 1):S65–S75. 2015.PubMed/NCBI View Article : Google Scholar
7	Lefebvre P, Cariou B, Lien F, Kuipers F and Staels B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 89:147–191. 2009.PubMed/NCBI View Article : Google Scholar
8	Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, et al: FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 6(33453)2016.PubMed/NCBI View Article : Google Scholar
9	Zhang DG, Zhang C, Wang JX, Wang BW, Wang H, Zhang ZH, Chen YH, Lu Y, Tao L, Wang JQ, et al: Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation. Toxicol Appl Pharmacol. 314:39–47. 2017.PubMed/NCBI View Article : Google Scholar
10	Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, et al: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 145:574–582.e1. 2013.PubMed/NCBI View Article : Google Scholar
11	Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, et al: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet. 385:956–965. 2015.PubMed/NCBI View Article : Google Scholar
12	Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, et al: REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 84(105803)2019.PubMed/NCBI View Article : Google Scholar
13	Briand F, Brousseau E, Quinsat M, Burcelin R and Sulpice T: Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model. Eur J Pharmacol. 818:449–456. 2018.PubMed/NCBI View Article : Google Scholar
14	Papazyan R, Liu X, Liu J, Dong B, Plummer EM, Lewis RD II, Roth JD and Young MA: FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res. 59:982–993. 2018.PubMed/NCBI View Article : Google Scholar
15	McTaggart F and Jones P: Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 22:321–338. 2008.PubMed/NCBI View Article : Google Scholar
16	Maron DJ, Fazio S and Linton MF: Current perspectives on statins. Circulation. 101:207–213. 2000.PubMed/NCBI View Article : Google Scholar
17	Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol. 44:358–365. 2009.PubMed/NCBI View Article : Google Scholar
18	Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Zhang HJ, Pan LL, Ma ZM, Chen Z, Huang ZF, Sun Q, Lu Y, Han CK, Lin MZ, Li XJ, et al: Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: A 1-year follow-up study. Diabetes Obes Metab. 19:284–289. 2017.PubMed/NCBI View Article : Google Scholar
21	Hoeke MO, Heegsma J, Hoekstra M, Moshage H and Faber KN: Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1. PLoS One. 9(e88011)2014.PubMed/NCBI View Article : Google Scholar
22	Chambers KF, Day PE, Aboufarrag HT and Kroon PA: Polyphenol effects on cholesterol metabolism via bile acid biosynthesis, CYP7A1: A review. Nutrients. 11(2588)2019.PubMed/NCBI View Article : Google Scholar
23	Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature. 343:425–430. 1990.PubMed/NCBI View Article : Google Scholar
24	Li D, Zhao D, Du J, Dong S, Aldhamin Z, Yuan X, Li W, Du H, Zhao W, Cui L, et al: Heme oxygenase-1 alleviated non-alcoholic fatty liver disease via suppressing ROS-dependent endoplasmic reticulum stress. Life Sci. 253(117678)2020.PubMed/NCBI View Article : Google Scholar
25	Pockros PJ, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz EJ, Hellstern PA, Owens-Grillo J, Van Biene C, Shringarpure R, et al: CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 39:2082–2093. 2019.PubMed/NCBI View Article : Google Scholar
26	Hu YB, Liu XY and Zhan W: Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Des Devel Ther. 12:2213–2221. 2018.PubMed/NCBI View Article : Google Scholar
27	Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH and Van Natta ML: NASH CRN. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 47:645–656. 2018.PubMed/NCBI View Article : Google Scholar
28	Tolbol KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N and Feigh M: Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 24:179–194. 2018.PubMed/NCBI View Article : Google Scholar
29	Kim SG, Kim BK, Kim K and Fang S: Bile acid nuclear receptor Farnesoid X receptor: Therapeutic target for nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 31:500–504. 2016.PubMed/NCBI View Article : Google Scholar
30	Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E and Fiorucci S: Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Biochim Biophys Acta Mol Cell Biol Lipids. 1864:1422–1437. 2019.PubMed/NCBI View Article : Google Scholar
31	Byun HW, Hong EM, Park SH, Koh DH, Choi MH, Jang HJ, Kae SH and Lee J: Pravastatin activates the expression of farnesoid X receptor and liver X receptor alpha in Hep3B cells. Hepatobiliary Pancreat Dis Int. 13:65–73. 2014.PubMed/NCBI View Article : Google Scholar
32	Fu ZD, Cui JY and Klaassen CD: Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. J Lipid Res. 55:2576–2586. 2014.PubMed/NCBI View Article : Google Scholar